|Bid||82.75 x 800|
|Ask||83.64 x 100|
|Day's Range||82.86 - 84.28|
|52 Week Range||63.76 - 86.27|
|PE Ratio (TTM)||9.08|
|Dividend & Yield||2.08 (2.53%)|
|1y Target Est||N/A|
Guggenheim Securities This report includes results from our proprietary survey regarding the potential early demand for chimeric antigen receptor T-cell (CAR-T) therapy. The survey includes responses from 25 hematologists/oncologists regarding the prospective use of CAR-T therapy in acute lymphoblastic leukemia (ALL) and diffuse large B-cell lymphoma (DLBCL) patients. The survey had begun prior to Gilead Sciences’ (GILD) announced acquisition of Kite Pharma (KITE) on Aug. 28 of this year.
In the fight against cancer, CAR T therapies are growing in popularity. Butler and Cha surveyed 25 hematologists/oncologists about their thoughts on potentially using CAR T therapy in appropriate patients within their practices, beginning before the Gilead-Kite Pharma deal was announced, and the results appear to be good news. From the note: Our findings suggest that the majority of surveyed hematologists/oncologists are familiar with CAR T therapy, and plan to use the therapy for either r/r ALL [relapsed and refractory acute lymphoblastic leukemia] or r/r DLBCL [diffuse large B-cell lymphoma] patients.
Optimism that it can develop CAR-T cancer drugs that are better than its competitors' is trumping news that the company is diluting investors by selling more shares.